Brain Metastasis, Non Small Cell Lung Cancer
Conditions
Keywords
EGFR mutant
Brief summary
EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.
Detailed description
no available
Interventions
RADIATIONwhole brain radiation(WBI)
WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
DRUGIcotinib
administered orally at a dose of 125 mg 3 times daily
Sponsors
Guangdong Provincial People's Hospital
Guangdong Association of Clinical Trials
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology. Patient who brain metastases was shown in MRI or CT scan. Brain metastases lesions should be more than 3.The diameter among these lesions should be more than 1 centimeter. Males or females aged ≥18 years, \< 75 years. Eastern Cooperative Oncology Group(ECOG) performance status 0-1. Life expectancy ≥12 weeks. The therapy of surgery,chemotherapy,radiotherapy that the patients were ever received should be more than 2 weeks ago.The patient had recovered from the treatment. Males and females should be contraceptive during the period of the trial until 8 weeks after the last administration of icotinib. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications. Written informed consent provided.
Exclusion criteria
Patient was received irradiation of brain. Patient with meningeal metastases were confirmed by MRI or cytology test of cerebrospinal fluid. Patient is received the treatment of Phenytoin, carbamazepine, rifampicin, phenobarbital, or St. John's Wort. Patient was received EGFR Tyrosine Kinase Inhibitor or EGFR monoclonal antibody. Interstitial pneumonia.Pericardial effusion, pleural effusion is uncontrolled . Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). Any significant ophthalmologic abnormality ,especially severe dry eye syndrome ,keratoconjunctivitis sicca,Sjogren syndrome,severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease. Female subjects should not be pregnant or breast-feeding. Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L. Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver function :Total bilirubin £ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase (ALT )and Aspartate Aminotransferase (AST )\< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases. The symptoms of increased intracranial pressure are uncontrolled after dehydration and cortisone treatment. Patient need increase irradiation dose after routine irradiation(30GY/10f/2w) Patient should treat extra cranial lesions first. Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| iPFS | 18 months | intracranial progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progress-free survival (PFS) | up to 16 months | progress-free survival |
| time of controlling brain metastasis symptom | 18months | time of controlling brain metastasis symptom |
| Cognitive function | 18months | Cognitive function |
| overall survival(OS) | 24months | overall survival(OS) |
| Response rate of brain metastasis | 12months | Response rate of brain metastasis |
Other
| Measure | Time frame | Description |
|---|---|---|
| Toxicity | 24months | adverse events(according to CTC4.0) |
Countries
China
Outcome results
None listed